Adaptimmune’s second T cell receptor cell therapy for rare sarcomas passes pivotal testnews2024-11-13T16:07:00+00:00November 13th, 2024|Endpoints News|
Neurogene’s stock falls in post-market trading after early data in Rett syndromenews2024-11-12T05:16:30+00:00November 12th, 2024|Endpoints News|
Aurion, Alcon enter legal battle over IPO plannews2024-11-11T11:30:23+00:00November 11th, 2024|Endpoints News|
Updated: FDA approves Autolus’ CAR-T cell therapy for aggressive blood cancernews2024-11-11T08:09:09+00:00November 11th, 2024|Endpoints News|
#ASH24: Gilead and Arcellx spotlight safety of multiple myeloma cell therapy, dose first patient in Phase 3news2024-11-05T16:08:48+00:00November 5th, 2024|Endpoints News|
#ASH24: Beam discloses first clinical data on base-edited sickle cell therapy, one patient deathnews2024-11-05T15:19:56+00:00November 5th, 2024|Endpoints News|
Exclusive: Blood stem cell therapy maker Garuda gets new CEO, adds $47Mnews2024-11-01T12:55:10+00:00November 1st, 2024|Endpoints News|
